The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study

The validation of assays that quantify antigen-specific T cell responses is critically dependent on cell samples that contain clearly defined measurable numbers of antigen-specific T cells. An important requirement is that such cell samples are handled and analyzed in a comparable fashion to peripheral blood mononuclear cells (PBMC). We performed a proof-of-principle study to show that retrovirally TCR-transduced T cells spiked at defined numbers in autologous PBMC can be used as standard samples for HLA/peptide multimer staining. NY-ESO-1157–165-specific, TCR-transduced CD8+ T cell batches were successfully generated from PBMC of several HLA-A*0201 healthy donors, purified by magnetic cell sorting on the basis of HLA tetramer (TM) staining and expanded with specific antigen in vitro. When subsequently spiked into autologous PBMC, the detection of these CD3+CD8+TM+ T cells was highly accurate with a mean accuracy of 91.6 %. The standard cells can be preserved for a substantial period of time in liquid nitrogen. Furthermore, TM staining of fresh and cryopreserved standard samples diluted at decreasing concentrations into autologous cryopreserved unspiked PBMC revealed that the spiked CD3+CD8+TM+ T cells could be accurately detected at all dilutions in a linear fashion with a goodness-of-fit of over 0.99 at a frequency of at least 0.02 % among the CD3+CD8+ T cell population. Notably, the CD3+CD8+TM+ cells of the standard samples were located exactly within the gates used to analyze patient samples and displayed a similar scatter pattern. The performance of the cryopreserved standard samples in the hands of 5 external investigators was good with an inter-laboratory variation of 32.9 % and the doubtless identification of one outlier.

[1]  Sylvia Janetzki,et al.  Harmonization of Immune Biomarker Assays for Clinical Studies , 2011, Science Translational Medicine.

[2]  M. Albert,et al.  Enumeration of human antigen-specific naive CD8+ T cells reveals conserved precursor frequencies. , 2010, Blood.

[3]  D. Speiser,et al.  Ex Vivo Analysis of Human Antigen-Specific CD8+ T-Cell Responses: Quality Assessment of Fluorescent HLA-A2 Multimer and Interferon-γ ELISPOT Assays for Patient Immune Monitoring , 2004, Journal of immunotherapy.

[4]  K. Rezvani,et al.  Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia. , 2009, Blood.

[5]  S. H. van der Burg,et al.  Identification of a conserved universal Th epitope in HIV-1 reverse transcriptase that is processed and presented to HIV-specific CD4+ T cells by at least four unrelated HLA-DR molecules. , 1999, Journal of immunology.

[6]  M. Perricone,et al.  Validation of a HLA-A2 tetramer flow cytometric method, IFNgamma real time RT-PCR, and IFNgamma ELISPOT for detection of immunologic response to gp100 and MelanA/MART-1 in melanoma patients , 2008, Journal of Translational Medicine.

[7]  D. Busch,et al.  Quantitation of MHC tetramer‐positive cells from whole blood: Evaluation of a single‐platform, six‐parameter flow cytometric method , 2004, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[8]  A. Mackensen,et al.  The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.

[9]  D. Speiser,et al.  Distinct sets of αβ TCRs confer similar recognition of tumor antigen NY-ESO-1157–165 by interacting with its central Met/Trp residues , 2008, Proceedings of the National Academy of Sciences.

[10]  F. Wong,et al.  Immunology of Diabetes Society T‐Cell Workshop: HLA class I tetramer‐directed epitope validation initiative T‐Cell Workshop Report—HLA Class I Tetramer Validation Initiative , 2011, Diabetes/metabolism research and reviews.

[11]  P. Schrier,et al.  Interleukin‐2‐induced, melanoma‐specific T cells recognize camel, an unexpected translation product of LAGE‐1 , 1999, International journal of cancer.

[12]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[13]  Cedrik M. Britten,et al.  Response definition criteria for ELISPOT assays revisited , 2010, Cancer Immunology, Immunotherapy.

[14]  B. Comin-Anduix,et al.  Definition of an Immunologic Response Using the Major Histocompatibility Complex Tetramer and Enzyme-Linked Immunospot Assays , 2006, Clinical Cancer Research.

[15]  L. J. Old,et al.  Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond , 2010, Cancer Immunology, Immunotherapy.

[16]  S. H. van der Burg,et al.  Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells , 2009, Cancer Immunology, Immunotherapy.

[17]  Sylvia Janetzki,et al.  "MIATA"-minimal information about T cell assays. , 2009, Immunity.

[18]  C. Gouttefangeas,et al.  Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program , 2010, Cancer Immunology, Immunotherapy.

[19]  P. Klenerman,et al.  Ultrasensitive Detection and Phenotyping of CD4+ T Cells with Optimized HLA Class II Tetramer Staining1 , 2005, The Journal of Immunology.

[20]  Cedrik M. Britten,et al.  Harmonization of the intracellular cytokine staining assay , 2012, Cancer Immunology, Immunotherapy.

[21]  Tak W. Mak,et al.  Human T-cell receptor variable gene segment families , 1995, Immunogenetics.